- Home
- JFR vs NBTX Comparison
JFR vs NBTX Comparison
Compare JFR & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | NBTX |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JFR | NBTX |
|---|---|---|
| Price | $7.49 | $33.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 855.8K | 43.6K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.16 | $3.13 |
| 52 Week High | $8.59 | $41.89 |
Technical Indicators
Market Signals| Indicator | JFR | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 55.28 |
| Support Level | $7.23 | $20.11 |
| Resistance Level | $7.61 | $34.66 |
| Average True Range (ATR) | 0.07 | 1.65 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 51.47 | 80.91 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.